USPTO serial 79373376
SYRCELT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 10, 2024
- Examiner
- MANCA, ALBERTO I
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SYRCELT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bradley M. Stohry
Bradley M. Stohry Reichel Stohry Dean LLP6151 Central AveIndianapolis, IN 46220United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products for use in the pharmaceutical industry, namely, chemical additives and preservatives for use in the manufacture of pharmaceuticals; active chemical ingredients for manufacture of pharmaceutical products for treating cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; chemical additives for use as binding agents in the manufacture of pharmaceuticals for treating cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; chemical carrier excipients for use in the manufacture of pharmaceutical preparations; chemical excipients for the manufacture of pharmaceutical preparations; raw material, namely, cellulose microspheres and microspheres made of cellulose, sugar, and starch for use in the manufacture of pharmaceuticals; microcrystalline cellulose microspheres for use in the manufacture of pharmaceuticals; preserving agents for the pharmaceutical industry, namely, antioxidants and antimicrobials for use in the manufacture of pharmaceuticals; carrier excipients for use in the manufacture of pharmaceutical preparations; excipients for pharmaceutical preparation manufacture | ACTIVE | — |
| 005 | Pharmaceutical products, namely, syrups, preparations in the form of granules, and liquid pharmaceutical suspensions, for pharmaceutical purposes for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases, and pharmaceutical preparations for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; medicines, namely, syrups, preparations in the form of granules, and liquid pharmaceutical suspensions, for pharmaceutical purposes for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents, namely, medicine release agents in the form of gastro-resistant and controlled release microparticles for the controlled release of active ingredients for a wide range of pharmaceutical products; drug delivery agents, namely, medicine delivery agents in the form of granulated powders for the controlled release of active ingredients for a wide range of pharmaceutical products; syrups for pharmaceutical use for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; syrups being medicines for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; syringes pre-filled with syrups for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; medicines being esomeprazole for oral administration; medicines being omeprazole for oral administration; central nervous system stimulants; hormones for medical use; Pharmaceutical products for the treatment of gastrointestinal disorders; soporifics | ACTIVE | — |
| 042 | Pharmaceutical research and development for the pharmaceutical industry; medical and pharmacological research services; research and development services relating to medicines; development of pharmaceutical preparations and medicines; development of pharmaceutical products | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BePharBel Manufacturing S.A.
- Other trademarks owned by BePharBel Manufacturing S.A.
- Other trademarks owned by BePharBel Manufacturing S.A.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named SYRCELT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 31, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 11, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 11, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 10, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 21, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 10, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 10, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 4, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 4, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 10, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 10, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 21, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 7, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 7, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 7, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 7, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 7, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 22, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 22, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 22, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 25, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 25, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 9, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 8, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 4, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 8, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 11, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 7, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 6, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |